Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19729334 | 0.87 | ITGB3 (0.38) | CHRNB2CHRNB4CHRNA4GAARAB9A | |
| SCHEMBL24932573 | 0.86 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL17773073 | 0.86 | CHRNB2 (0.30) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL26894997 | 0.86 | ALOX15 (0.31) | CHRNB2CHRNB4CHRNA4SMN1; SMN2 | |
| SCHEMBL26894992 | 0.79 | — | — | |
| SCHEMBL13254058 | 0.77 | ITGB3 (0.34) | SMN1; SMN2 | |
| SCHEMBL23489658 | 0.77 | ITGB3 (0.34) | SMN1; SMN2 | |
| SCHEMBL13347956 | 0.74 | ALOX15 (0.35) | SMN1; SMN2 | |
| SCHEMBL18758148 | 0.74 | NPY4R (0.42) | — | |
| SCHEMBL13971371 | 0.73 | ALOX15 (0.37) | ALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362238-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ALDH1A1 3359/4885TDP1 536/4885CHRNB2 4340/4885 |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | ALDH1A1 3359/4885TDP1 536/4885CHRNB2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.